Spark Therapeutics is developing SPK-8011, an investigational gene therapy for hemophilia A, or factor VIII deficiency. Hemophilia A is a serious and rare inherited hematologic disorder, characterized by mutations in the F8 gene, which lead to deficient blood coagulation and an increased risk of bleeding or hemorrhaging.
Spark® Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: 1-855-SPARKTX / +1 215-220-9300
